Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging

Atherosclerosis Clinical Trial

Official title:

Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00251615
• Other study ID #: AG0058
• Status: Completed
• Phase: N/A
• First received: November 8, 2005
• Last updated: August 3, 2012
• Start date: August 2012
• Est. completion date: August 2012

Study information

• Verified date: August 2012
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn what changes in blood vessel contraction may occur as a result of a disease of the vessel that requires surgery. The study will examine the calcium channels present in the vessels being operated on, and the genes that may alter blood vessel function. Possible variation in these genes may change the kind of calcium channels present in blood vessels.

Description:

The goal of this study is to learn more about how blood vessels function and the mechanism that causes them to contract. The study will investigate the natural history of diseased blood vessel tissue and the calcium channels in the muscle part of the blood vessel. The study will also examine how genetics influences cardiovascular disease and its causes and treatments.

Patients scheduled for vascular surgery will be approached to participate in this study. During surgery, tissue fragments of diseased and marginal tissue will be obtained. A blood sample will be obtained at either the time of surgery or consent and genomic DNA will be extracted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Ages 21 and older

• Scheduled for vascular surgery

Exclusion Criteria:

• Unwillingness to be subjected to diagnostic and/or therapeutic procedures that are deemed not necessary for clinical management

• Volunteers deemed too fragile to participate in the study by the principal investigator (PI) or the attending physician

• Inability to obtain informed consent from either the volunteer or the responsible party (durable power of attorney [DPA]) for the volunteer, with the volunteer's assent

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Atherosclerosis
• Cardiovascular Diseases

Locations

Country	Name	City	State
United States	National Institute on Aging, Harbor Hospital	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Abernethy DR, Soldatov NM. Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. J Pharmacol Exp Ther. 2002 Mar;300(3):724-8. Review. — View Citation

Harry JB, Kobrinsky E, Abernethy DR, Soldatov NM. New short splice variants of the human cardiac Cavbeta2 subunit: redefining the major functional motifs implemented in modulation of the Cav1.2 channel. J Biol Chem. 2004 Nov 5;279(45):46367-72. Epub 2004 Aug 31. — View Citation

Kobrinsky E, Tiwari S, Maltsev VA, Harry JB, Lakatta E, Abernethy DR, Soldatov NM. Differential role of the alpha1C subunit tails in regulation of the Cav1.2 channel by membrane potential, beta subunits, and Ca2+ ions. J Biol Chem. 2005 Apr 1;280(13):12474-85. Epub 2005 Jan 25. — View Citation